Answers are grounded in this paper and cite their sources.
Back pain is one of the leading causes of visits to the doctor and disability worldwide. Patients with acute, subacute, or exacerbated chronic back pain are prescribed non-steroidal anti-inflammatory drugs, and muscle relaxants as co-analgesics. Thiocolchicoside is an effective muscle relaxant widely known worldwide, whose action is realized through effects on GABA-A and glycinergic receptors and modulation of spinal neural circuits. Thiocolchicoside is not metabolized by the CYP450 cytochrome, which results in a low risk of pharmacokinetic drug interactions, and it has an optimal safety profile: it does not have a pronounced sedative effect, does not cause arterial hypotension, and does not increase the risk of genotoxicity. Depending on the clinical situation, a patient with back pain and a painful muscle spasm may be prescribed various dosages and formulations of thiocolchicoside: capsules containing 4–8 mg orally twice a day for 7 days, or intramuscular injections of thiocolchicoside containing 4 mg (2 ml) twice a day for 5 days.
No takes yet. Share an insight, caveat, or question.
Tatiana I. Nasonova (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: